Hint of gloss comes off Keytruda as trials are halted

6 July 2017
2019_biotech_test_vial_discovery_big

Merck & Co (NYSE: MRK) looked set to open 1% down on Thursday at around $63.50 after some rare bad news relating to Keytruda (pembrolizumab).

The anti-PD-1 therapy has been leading the immuno-oncology charge in multiple cancer types, but the US Food and Drug Administration (FDA) on Wednesday placed a clinical hold on three multiple myeloma studies of Keytruda in combination with other drugs.

This decision follows a review of data by the Data Monitoring Committee in which more deaths were observed in the Keytruda arms of the KEYNOTE-183 and KEYNOTE-185 studies, leading to the pause in new patient enrollment announced last month.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology